Potentially inappropriate medications in older individuals with diabetes: A population-based study in Quebec, Canada.
Age Factors
Aged
Aged, 80 and over
Comorbidity
Databases, Factual
Diabetes Mellitus
/ diagnosis
Drug Interactions
Drug-Related Side Effects and Adverse Reactions
/ diagnosis
Female
Humans
Hypoglycemic Agents
/ adverse effects
Inappropriate Prescribing
Male
Polypharmacy
Quebec
/ epidemiology
Risk Assessment
Risk Factors
Sex Factors
Beers criteria
Potentially inappropriate medications
diabetes
older adults
polypharmacy
Journal
Primary care diabetes
ISSN: 1878-0210
Titre abrégé: Prim Care Diabetes
Pays: England
ID NLM: 101463825
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
14
06
2019
revised:
06
02
2020
accepted:
26
03
2020
pubmed:
14
5
2020
medline:
18
8
2021
entrez:
14
5
2020
Statut:
ppublish
Résumé
To study the population-based prevalence of potentially inappropriate medication (PIM) among older individuals with diabetes, and to identify factors associated with their use. We used the Quebec Integrated Chronic Disease Surveillance System (QICDSS) database to conduct a population-based cohort study of individuals with diabetes ≥66 years between April 1st, 2014 and March 31st, 2015. PIMs were defined according to the 2015 Beers Criteria. Factors associated with PIM use were identified using robust Poisson regression models. Risk ratios (RR) and 99% confidence intervals (99%CI) were calculated. More than half (56%) of the 286,962 older individuals with diabetes used at least one PIM over a year. Benzodiazepines (41%), proton pump inhibitors (27%) and endocrine medication (mainly glibenclamide) (25%) were the most common PIMs used. Factors associated with PIM use included female sex (RR: 1.17; 99%CI: 1.16-1.18), and comorbidities such as schizophrenia (1.48; 1.45-1.51), anxiety disorders (1.34; 1.33-1.35) and Alzheimer's disease (1.14; 1.13-1.25). Risks of using PIMs increased both with increasing comorbidities and number of medications. PIM use is highly prevalent among older individuals with diabetes. Interventions to promote optimal medication use should particularly target individuals with comorbidities and polypharmacy who are most vulnerable to adverse drug events.
Identifiants
pubmed: 32402848
pii: S1751-9918(20)30166-2
doi: 10.1016/j.pcd.2020.03.003
pii:
doi:
Substances chimiques
Hypoglycemic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
529-537Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
Copyright © 2020 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.